Accendra Health, Inc. · NYSE:ACH
Accendra Health — Owens & Minor — Merger or Acquisition (July 2024)
15 slides from Accendra Health's merger presentation, Jul 23, 2024
Slide 1: Rotech – Investor Presentation
Exhibit 99.2 Rotech – Investor Presentation July 23, 2024
Slide 2: Disclaimer
Disclaimer This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC's Fair Disclosure Regulation. This presentation contains certain “forward-looking” statements made pursuant to the Sa
Slide 3: Transaction Overview
Transaction Overview Key Stats Strategic Rationale Financial Implications 2024 Update § Purchase price of $1.36 § Improves Patient Direct § Accelerates top line and § Q2 2024 revenue of $2.65 – earnings growth $2.67 billion, net loss of billion in cash or $1.32 capabilities (1) billion net of tax be
Slide 4: Compelling Strategic Rationale and Value Creation Opportunity
Compelling Strategic Rationale and Value Creation Opportunity Strategic Rationale Value Creation Strengthens Patient Direct by expanding product offerings through expansion Accelerates long-term across complementary portfolios and provides access to the Durable Medical Equipment revenue growth (DME)
Slide 5: Rotech at-a-Glance
Rotech at-a-Glance Key Stats Proven Track Record § Best-in-class Home Medical Equipment distributor ~$750mm § Partner of choice for many payors, providers, suppliers and patients 2023A Net Revenue § 40+ years in operation led by a seasoned management team with 100+ years of combined experience $200m
Slide 6: Rotech Further Diversifies our Patient Direct Business
Rotech Further Diversifies our Patient Direct Business 2023A Pro Forma Patient Direct Business Mix 2023A Pro Forma Patient Direct Payor Mix VA & Other Medicaid 1% 4% Urology 3% (1) Other Ostomy 10% 5% Sleep 28% Wound Care Medicare 6% 27% Commercial (2) 68% Diabetes 23% Respiratory 24% Key Business M
Slide 7: Alignment with Our Patient Direct Vision
Alignment with Our Patient Direct Vision Rotech Advances the Patient Direct 2028 Vision Framing the 2028 Patient Direct Vision Presented at Investor Day Patient Direct Revenue of $5 billion or more Strong brand recognition with a national footprint and local presence Proven model is expected to cont
Slide 8: Financial Implications
Financial Implications • Further scales business and accelerates company long-term growth rate Sales & Growth • Ability to leverage sizable combined network with ~625 locations • Accretive to operating and EBITDA margins • Improves Owens & Minor free cash flow generation Earnings & Returns • Adjuste
Slide 9: Maintain 2024 Company Outlook & Q2 Preliminary Results
Maintain 2024 Company Outlook & Q2 Preliminary Results (1) $ in million, except per share data 2024 Outlook Revenue $10,500 - $10,900 Adjusted EBITDA $550 - $590 Adjusted EPS $1.40 - $1.70 (2) $ in million, except per share data or when otherwise noted Selected Preliminary Financial Results for Q2 2
Slide 10: Summary of Key Investment Highlights
Summary of Key Investment Highlights Advances strategy articulated at Investor Day by strengthening Patient Direct’s position as a premier growth platform in 1 home-based care Combined capabilities and reach to support improved service to patients, providers and payors 2 Enables Owens & Minor to mor
Slide 11: Appendix
• • • A P P E N D I X • • •
Slide 12: GAAP/Non-GAAP Reconciliations
GAAP/Non-GAAP Reconciliations Three Months Ended June 30, 2024 $ in millions Low High Operating income, as reported (GAAP) $ 16 $ 20 (1) Acquisition-related charges and intangible amortization 20 20 (2) Exit and realignment charges, net 29 29 (3) Litigation and related charges 7 7 Operating income,
Slide 13: GAAP/Non-GAAP Reconciliations (Continued)
GAAP/Non-GAAP Reconciliations (Continued) Three Months Ended June 30, 2024 Low High Net loss per share, as reported (GAAP) $ (0.46) $ (0.42) After-tax adjustments: (1) Acquisition-related charges and intangible amortization 0.19 0.19 (2) Exit and realignment charges, net 0.29 0.29 (3) Litigation and
Slide 14: GAAP/Non-GAAP Reconciliations (Continued)
GAAP/Non-GAAP Reconciliations (Continued) Three Months Ended June 30, 2024 $ in millions Low High Net loss, as reported (GAAP) $ (35) $ (32) Income tax provision 15 16 Interest expense, net 36 36 (1) Acquisition-related charges and intangible amortization 20 20 (2) Exit and realignment charges, net
Slide 15: Definitions of Non-GAAP Reconciliation Items
Definitions of Non-GAAP Reconciliation Items (1) Acquisition-related charges and intangible amortization includes one-time costs related to the expected acquisition of Rotech, including legal and other professional fees, and amortization of intangible assets established during acquisition method of